en · de · es · fr · pt
bench-notes.peptides1126.com › Data › Tesamorelin �ƒŒ景与作用机制 — Reference Sheet

Tesamorelin �ƒŒ景与作用机制 — Reference Sheet

By Editorial Desk · published 2025-10-10 · last reviewed 2025-11-18 · Data

GHRH analog raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

This page was last updated on 2025-11-18 and is reviewed periodically as new material appears.

tesamorelin 背景与作用机制

作用位置在垂体前叶。tesamorelin 与 GHRH 受体结合后激活腺苷酸环化酶,升高细胞内 cAMP,再经蛋白激酶 A 通路促进生长激素的合成与释放。由于它作用于内源调控节点,生长激素仍以脉冲方式分泌,而不是被持续抬升到固定水平。生长激素随后在肝脏等组织诱导胰岛素样生长因子 1 产生,构成完整的生长激素轴响应。

研究背景集中在特定人群的体成分改变,尤其是与脂肪分布异常相关的内脏脂肪堆积。不同地区对它的监管状态与获批适应症并不一致,部分市场仅限特定诊断人群使用。在一般人群中的长期效应、与其他激素的相互作用以及停药后的维持情况仍属开放问题,现有数据不足以给出普遍结论。

tesamorelin 是一种人工合成的四十四肽,序列与内源性生长激素释放激素(GHRH)的 1-44 片段一致,区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割,从而延长分子在循环中的存留时间。作为肽类分子,它难以经胃肠道吸收,文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物,以区别于生长激素本身。

Mechanism and Pharmacodynamics

Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.

Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.

Tesamorelin at a glance

性质取值备注
分子类型合成四十四肽GHRH 类似物
N 端修饰反式-3-己烯酰基延缓酶切
分子量约 5135 Da依序列与修饰
受体靶点垂体 GHRH 受体经 cAMP 通路
常见同义名GHRH(1-44) 类似物文献通用称法

Background and Pharmacology of Tesamorelin

Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.

Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.

Related pages on this site

Mechanism And Measurement Approaches

Tesamorelin binds the growth hormone–releasing hormone receptor on pituitary somatotroph cells. The receptor signals through the Gs protein, raising intracellular cAMP and activating protein kinase A. That cascade triggers release of stored growth hormone in pulses rather than a steady stream. Because the drug acts at the receptor that normally controls this process, its effect depends on the body's own signaling architecture rather than on a synthetic pathway. The resulting hormone profile reflects the timing of each pulse, not only its size.

Measured responses usually involve growth hormone and insulin-like growth factor 1, known as IGF-1. Growth hormone rises in bursts and is difficult to sample reliably, while IGF-1 shifts more slowly and can be assessed from a single blood draw. Studies therefore treat IGF-1 as the more practical pharmacodynamic marker. Both are indirect, showing that the receptor was engaged rather than that the peptide reached a particular concentration. Direct exposure measurement requires an assay aimed at the molecule itself.

Tesamorelin Background and Mechanism

Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.

Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.

A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.

Mechanism and Research Endpoints

Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.

Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.

Background from the literature

On the first day of June, which would be known as "Black Friday", 521 B-29s escorted by 148 P-51s were dispatched in a daylight raid against Osaka. While en route to the city, the Mustangs flew through thick clouds, and 27 of the fighters were destroyed in collisions. Nevertheless, 458 heavy bombers and 27 P-51s reached the city, and the bombardment killed 3,960 Japanese and destroyed 3.15 square miles (8.2 km2) of buildings. On 5 June 473 B-29s struck Kobe by day and destroyed 4.35 square miles (11.3 km2) of buildings for the loss of 11 bombers. A force of 409 B-29s attacked Osaka again on 7 June; during this attack, 2.21 square miles (5.7 km2) of buildings were burnt out and the Americans did not suffer any losses. Osaka was bombed for the fourth time that month, on 15 June, when 444 B-29s destroyed 1.9 square miles (4.9 km2) of the city and another 0.59 square miles (1.5 km2) of nearby Amagasaki; 300,000 houses were destroyed in Osaka. This attack marked the end of the first phase of XXI Bomber Command's attack on Japan's cities. During May and June, the bombers had destroyed much of the country's six largest cities, killing between 112,000 and 126,762 people and rendering millions homeless. The widespread destruction and high number of casualties from these raids caused many Japanese to realize that their country's military was no longer able to defend the home islands. American losses were low compared to Japanese casualties; 136 B-29s were downed during the campaign. In Tokyo, Osaka, Nagoya, Yokohama, Kobe, and Kawasaki, "over 126,762 people were killed ...

== Deficiency == Complement defects are associated with an increased risk of infectious or local and inflammatory thrombotic disorders. These complement-linked disorders are rare but tend to show up during childhood. Hereditary angioedema (HAE) result from impaired function of the C1 inhibitor, and complement disorders result in renal disorders, including atypical hemolytic uremic syndrome (aHUS) or C3 glomerulopathy (C3G). Properdin deficiency is a rare X-linked disease in which properdin is deficient. Affected individuals are susceptible to fulminant meningococcal disease, whereas defects of the classical pathway increase the risk of autoimmune disorders. Properdin deficiency has been reported in more than 70 patients, and is linked to infections with Neisseria meningitides and Neisseria gonorrhoea. Mortality rates are higher in individuals with properdin deficiency in comparison to those with terminal complement deficiencies. Three classes of properdin deficiencies are

=== Microscopic features === Psilocybe baeocystis spores are dark purplish brown in deposit, oblong in face view or asymmetric ellipsoid (mango form) in side view, and are (8.5) 9.5–13.7(17) x (5) 5.5–6.6(7.1) μm. The basidia are 4-spored, and pleurocystidia are absent. The cheilocystidia are 20–30(40) x 4.5–6(9) μm and fusiod with a narrow neck. This species closely resembles subtropical Psilocybe aztecorum and Psilocybe quebecensis, which also have caps that bleach in color to white when dry.

A disintegrin and metalloproteinase with thrombospondin motifs 7 (ADAMTS7) is an enzyme that in humans is encoded by the ADAMTS7 gene on chromosome 15. It is ubiquitously expressed in many tissues and cell types. This enzyme was historically reported to catalyze the degradation of cartilage oligomeric matrix protein (COMP), though subsequent studies using purified proteins and unbiased mass spectrometry found that ADAMTS7 does not cleave COMP. ADAMTS7 has been associated with cancer and arthritis in multiple tissue types. The ADAMTS7 gene is a well-established genetic susceptibility locus for coronary artery disease.

Concentrations of taste buds vary from species to species, with bullhead catfish having 25 buds in a square millimeter of barbel skin. Barbels begin to develop during the embryonic, larval, or juvenile life stages of most of the species in which they are present. Development regulation of barbels has been linked to the C-C motif ligand 33 of the chemokine family of genes, due to its presence in barbeled catfish and zebrafish and absence or difference in expression in barbel-less members of the same families. This class of genes are signalling genes that provide migrating cells directional information during morphogenesis.

Sources: en.wikipedia.org

Reference notes

This can be used as the basis for biosensors. Once assembled, the two separate DNA strands can be ligated into a single strand. Unmodified aptamers are cleared rapidly from the bloodstream, with a half-life of seconds to hours. This is mainly due to nuclease degradation, which physically destroys the aptamers, as well as clearance by the kidneys, a result of the aptamer's low molecular weight and size. Several modifications, such as 2'-fluorine-substituted pyrimidines and polyethylene glycol (PEG) linkage, permit a serum half-life of days to weeks. PEGylation can add sufficient mass and size to prevent clearance by the kidneys in vivo. Unmodified aptamers can treat coagulation disorders. The problem of clearance and nuclease digestion is diminished when they are applied to the eye, where there is a lower concentration of nuclease and the rate of clearance is lower. Rapid clearance from serum can also be useful in some applications, such as in vivo diagnostic imaging. In a study on aptamers designed to bind with proteins associated with Ebola infection, a comparison was made among three aptamers isolated for their ability to bind the target protein EBOV sGP. Although these aptamers vary in both sequence and structure, they exhibit remarkably similar relative affinities for sGP from EBOV and SUDV, as well as EBOV GP1.2. Notably, these aptamers demonstrated a high degree of specificity for the GP gene products.

==== Food industry ==== The PEG–NaCl system has been shown to be effective at partitioning small molecules, such as peptides and nucleic acids. These compounds are often flavorants or odorants. The system could then be used by the food industry to isolate or eliminate particular flavors. Caffeine extraction used to be done using liquid–liquid extraction, specifically direct and indirect liquid–liquid extraction (Swiss Water Method), but has since moved towards super-critical CO2 as it is cheaper and can be done on a commercial scale.

Chymopapain (EC 3.4.22.6, chymopapain A, chymopapain B, chymopapain S, brand name Chymodiactin) is a proteolytic enzyme isolated from the latex of papaya (Carica papaya). It is a cysteine protease which belongs to the papain-like protease (PLCP) group. Because of its proteolytic activity, it is the main molecule in the process of chemonucleolysis, used in some procedures like the treatment of herniated lower lumbar discs in the spine by a nonsurgical method.

==== Malaria ==== The President's Malaria Initiative, started with help from George W. Bush, has contributed to a more than 60% reduction in malaria deaths, saved 7.6 million lives, and prevented 1.5 billion malaria cases globally between 2000 and 2019. PMI has supported malaria prevention and control for over 500 million at-risk people in Africa. However, the USAID funding of PMI has been cut an estimated 47% as of June 2025. In countries such as the Democratic Republic of the Congo (DRC), these funds had supported the supply of antimalarial drugs to numerous health zones, including preventive treatments for pregnant women. Health officials in the DRC reported that the effects of these cuts were already being felt, with increased risk of severe illness and death from malaria among vulnerable populations. Former aid workers and experts also expressed concern that reduced funding undermined disease surveillance systems that help detect malaria and other outbreaks early. Such surveillance not only protects affected countries but also contributes to U.S. health security by limiting the global spread of disease. Aid organizations also highlighted how these cuts create a "vicious cycle," with malnutrition and malaria reinforcing one another. Reductions in U.S. support for nutrition programs increase children's vulnerability to malaria and other diseases, while higher malaria infections can worsen malnutrition.

Sources: en.wikipedia.org

Notes from published material

The majority of mothers intend to breastfeed at birth. Many factors can disrupt this intent. Research done in the US shows that obstetricians rarely provide information about breastfeeding during their prenatal visits, and some health professionals incorrectly believe that commercially prepared formula is nutritionally equivalent to breast milk. Many hospitals have instituted practices that encourage breastfeeding, however a 2012 survey in the US found that 24% of maternity services were still providing supplements of commercial infant formula as a general practice in the first 48 hours after birth. The Surgeon General's Call to Action to Support Breastfeeding attempts to educate practitioners.

== Diagnosis == The diagnosis of MADD needs to be considered in patients who have exercise induced myalgia, cramps and sometimes weakness. A mildly elevated creatine kinase may also occur. Exclusion of other muscular diseases such as McArdle's Disease and carnitine cycle abnormalities should occur. MADD may be identified if there is a lack of ammonia rise after forearm exercise testing. The diagnosis may then be confirmed with genetic testing.

To make new legislation, TFEU article 294 defines the "ordinary legislative procedure" that applies for most EU acts. The essence is there are three readings, starting with a Commission proposal, where the Parliament must vote by a majority of all MEPs (not just those present) to block or suggest changes, and the Council must vote by qualified majority to approve changes, but by unanimity to block Commission amendment. Where the different institutions cannot agree at any stage, a "Conciliation Committee" is convened, representing MEPs, ministers and the commission to try to get agreement on a joint text: if this works, it will be sent back to the Parliament and Council to approve by absolute and qualified majority. This means, legislation can be blocked by a majority in Parliament, a minority in the council, and a majority in the commission: it is harder to change EU law than for it to stay the same. A different procedure exists for budgets. For "enhanced cooperation" among a sub-set of at least member states, authorisation must be given by the council. Member state governments should be informed by the Commission at the outset before any proposals start the legislative procedure. The EU as a whole can only act within its power set out in the Treaties. TEU articles 4 and 5 state that powers remain with the member states unless they have been conferred, although there is a debate about the Kompetenz-Kompetenz question: who ultimately has the "competence" to define the EU's "competence".

Sources: en.wikipedia.org

Frequently asked questions

tesamorelin 与生长激素有什么区别?

tesamorelin 属 GHRH 类似物,作用于垂体受体以促进内源生长激素释放;生长激素本身是直接补充的外源激素。两者在给药逻辑、作用位点和反馈调控路径上并不相同。

它通常以何种方式进入体内?

作为多肽,它难以通过胃肠道吸收,通常需要注射给药。口服会因消化酶降解而失去活性,因此文献中讨论的都是注射途径。

目前研究主要关注哪些方向?

公开研究多集中在内脏脂肪、体成分分布以及与生长激素轴相关的代谢指标。长期安全性和在普通人群中的适用性尚缺乏一致结论。

What receptor does tesamorelin target?

It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Binding stimulates cyclic AMP signaling and growth hormone secretion. This is the same receptor used by endogenous GHRH.

Network